Survival rates of systemic interventions for psoriasis in the Western Japan Psoriasis Registry: A multicenter retrospective study
Corresponding Author
Tetsuji Yanase
Department of Dermatology, Hiroshima City North Medical Center Asa Citizens Hospital, Hiroshima, Japan
Correspondence
Tetsuji Yanase, Department of Dermatology, Hiroshima City North Medical Center Asa Citizens Hospital, 1-2-1, Kameyamaminami, Asakita-ku, Hiroshima City, 731-0293, Hiroshima, Japan.
Email: [email protected]
Search for more papers by this authorNoriko Tsuruta
Department of Dermatology, Fukuoka University Faculty of Medicine, Fukuoka, Japan
Department of Dermatology, Kitakyuhsu City Yahata Hospital, Kitakyushu, Japan
Search for more papers by this authorKazuki Yamaguchi
Department of Dermatology, Fukuoka University Faculty of Medicine, Fukuoka, Japan
Department of Dermatology, Saiseikai Futsukaichi Hospital, Fukuoka, Japan
Search for more papers by this authorChika Ohata
Department of Dermatology, Kurume University School of Medicine, Kurume, Japan
Department of Dermatology, Osaka General Medical Center, Osaka, Japan
Search for more papers by this authorBungo Ohyama
Department of Dermatology, Kurume University School of Medicine, Kurume, Japan
Ohyama Dermatology Clinic, Kumamoto, Japan
Search for more papers by this authorEri Katayama
Department of Dermatology, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorKazunari Sugita
Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Tottori University Faculty of Medicine, Yonago, Japan
Search for more papers by this authorMaki Kuwashiro
Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
Search for more papers by this authorAki Hashimoto
Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
Search for more papers by this authorKentaro Yonekura
Department of Dermatology, Imamura General Hospital, Kagoshima, Japan
Search for more papers by this authorYuko Higashi
Department of Dermatology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
Search for more papers by this authorHiroyuki Murota
Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Search for more papers by this authorYuta Koike
Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Search for more papers by this authorYuki Matsuzaka
Department of Dermatology, Onomichi General Hospital, Onomichi, Japan
Search for more papers by this authorSatoko Kikuchi
Department of Dermatology, Kyushu Central Hospital, Fukuoka, Japan
Search for more papers by this authorYutaka Hatano
Department of Dermatology, Faculty of Medicine, Oita University, Yufu, Japan
Search for more papers by this authorKanami Saito
Department of Dermatology, Faculty of Medicine, Oita University, Yufu, Japan
Search for more papers by this authorKenzo Takahashi
Department of Dermatology, Graduate School of Medicine University of the Ryukyus, Nishihara, Japan
Search for more papers by this authorTakuya Miyagi
Department of Dermatology, Graduate School of Medicine University of the Ryukyus, Nishihara, Japan
Search for more papers by this authorSakae Kaneko
Department of Dermatology, Shimane University Faculty of Medicine, Izumo, Japan
Department of Dermatology, Masuda Red Cross Hospital, Masuda, Japan
Search for more papers by this authorMasataka Ota
Department of Dermatology, Shimane University Faculty of Medicine, Izumo, Japan
Search for more papers by this authorKayo Harada
Department of Dermatology and Allergy, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan
Search for more papers by this authorShin Morizane
Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
Search for more papers by this authorKenta Ikeda
Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
Search for more papers by this authorMasutaka Furue
Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorTakeshi Nakahara
Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorFusako Okazaki
Department of Dermatology, Okayama City General Medicine Center, Okayama, Japan
Search for more papers by this authorNatsuko Sasaki
Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan
Search for more papers by this authorEtsuko Okada
Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan
Search for more papers by this authorYuichi Yoshida
Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Tottori University Faculty of Medicine, Yonago, Japan
Search for more papers by this authorKotaro Ito
Department of Dermatology, Fukuoka University Faculty of Medicine, Fukuoka, Japan
Ito Medical Clinic, Dermatology, Kitsuki, Japan
Search for more papers by this authorShinichi Imafuku
Department of Dermatology, Fukuoka University Faculty of Medicine, Fukuoka, Japan
Search for more papers by this authorCorresponding Author
Tetsuji Yanase
Department of Dermatology, Hiroshima City North Medical Center Asa Citizens Hospital, Hiroshima, Japan
Correspondence
Tetsuji Yanase, Department of Dermatology, Hiroshima City North Medical Center Asa Citizens Hospital, 1-2-1, Kameyamaminami, Asakita-ku, Hiroshima City, 731-0293, Hiroshima, Japan.
Email: [email protected]
Search for more papers by this authorNoriko Tsuruta
Department of Dermatology, Fukuoka University Faculty of Medicine, Fukuoka, Japan
Department of Dermatology, Kitakyuhsu City Yahata Hospital, Kitakyushu, Japan
Search for more papers by this authorKazuki Yamaguchi
Department of Dermatology, Fukuoka University Faculty of Medicine, Fukuoka, Japan
Department of Dermatology, Saiseikai Futsukaichi Hospital, Fukuoka, Japan
Search for more papers by this authorChika Ohata
Department of Dermatology, Kurume University School of Medicine, Kurume, Japan
Department of Dermatology, Osaka General Medical Center, Osaka, Japan
Search for more papers by this authorBungo Ohyama
Department of Dermatology, Kurume University School of Medicine, Kurume, Japan
Ohyama Dermatology Clinic, Kumamoto, Japan
Search for more papers by this authorEri Katayama
Department of Dermatology, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorKazunari Sugita
Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Tottori University Faculty of Medicine, Yonago, Japan
Search for more papers by this authorMaki Kuwashiro
Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
Search for more papers by this authorAki Hashimoto
Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
Search for more papers by this authorKentaro Yonekura
Department of Dermatology, Imamura General Hospital, Kagoshima, Japan
Search for more papers by this authorYuko Higashi
Department of Dermatology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
Search for more papers by this authorHiroyuki Murota
Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Search for more papers by this authorYuta Koike
Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Search for more papers by this authorYuki Matsuzaka
Department of Dermatology, Onomichi General Hospital, Onomichi, Japan
Search for more papers by this authorSatoko Kikuchi
Department of Dermatology, Kyushu Central Hospital, Fukuoka, Japan
Search for more papers by this authorYutaka Hatano
Department of Dermatology, Faculty of Medicine, Oita University, Yufu, Japan
Search for more papers by this authorKanami Saito
Department of Dermatology, Faculty of Medicine, Oita University, Yufu, Japan
Search for more papers by this authorKenzo Takahashi
Department of Dermatology, Graduate School of Medicine University of the Ryukyus, Nishihara, Japan
Search for more papers by this authorTakuya Miyagi
Department of Dermatology, Graduate School of Medicine University of the Ryukyus, Nishihara, Japan
Search for more papers by this authorSakae Kaneko
Department of Dermatology, Shimane University Faculty of Medicine, Izumo, Japan
Department of Dermatology, Masuda Red Cross Hospital, Masuda, Japan
Search for more papers by this authorMasataka Ota
Department of Dermatology, Shimane University Faculty of Medicine, Izumo, Japan
Search for more papers by this authorKayo Harada
Department of Dermatology and Allergy, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan
Search for more papers by this authorShin Morizane
Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
Search for more papers by this authorKenta Ikeda
Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
Search for more papers by this authorMasutaka Furue
Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorTakeshi Nakahara
Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorFusako Okazaki
Department of Dermatology, Okayama City General Medicine Center, Okayama, Japan
Search for more papers by this authorNatsuko Sasaki
Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan
Search for more papers by this authorEtsuko Okada
Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan
Search for more papers by this authorYuichi Yoshida
Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Tottori University Faculty of Medicine, Yonago, Japan
Search for more papers by this authorKotaro Ito
Department of Dermatology, Fukuoka University Faculty of Medicine, Fukuoka, Japan
Ito Medical Clinic, Dermatology, Kitsuki, Japan
Search for more papers by this authorShinichi Imafuku
Department of Dermatology, Fukuoka University Faculty of Medicine, Fukuoka, Japan
Search for more papers by this authorSee Appendix 1 for the authors present in the Western Japan Inflammatory Disease Research Group.
Abstract
Psoriasis affects approximately 0.3% of the Japanese population. Recently, various effective systemic drugs have become available, and the continuation of a given treatment has become critical because of the chronic nature of psoriasis. Factors affecting drug survival (the time until treatment discontinuation) in psoriasis treatment include efficacy, safety, ease of use, and patient preference. In the present study, the authors retrospectively surveyed a multifacility patient registry to determine the real-world evidence of the survival rate of systemic interventions for psoriasis treatment. Patients with psoriasis who visited 20 facilities in the Western Japan area between January 2019 and May 2020 and gave written consent were registered as study participants, and their medical history of systemic interventions for psoriasis (starting from 2010) was retrospectively collected and analyzed. The drugs investigated were adalimumab, infliximab, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, cyclosporine, and apremilast. When drugs were discontinued, the reasons were also recorded. A total of 1003 patients with psoriasis including 268 with psoriatic arthritis (PsA) were enrolled. In biologics, more recently released drugs such as interleukin 17 inhibitors showed a numerically higher survival rate in the overall (post-2010) analysis. However, in the subset of patients who began treatment after 2017, the difference in the survival rate among the drugs was smaller. The reasons for discontinuing drugs varied, but a loss of efficacy against dermatological or joint symptoms were relatively frequently seen with some biologics and cyclosporine. The stratification of drug survival rates based on patient characteristics such as bio-naive or experienced, normal weight or obese, and with or without PsA, revealed that bio-experienced, obese, and PsA groups had poorer survival rates for most drugs. No notable safety issues were identified in this study. Overall, the present study revealed that the biologics show differences in their tendency to develop a loss of efficacy, and the factors that negatively impact the survival rate of biologics include the previous use of biologics, obesity, and PsA.
CONFLICT OF INTEREST Statement
Data for this research were collected from the WJPR. WJPR is run by an NPO, the Western Japan Inflammatory Skin Disease Research Group. This NPO receives funding support from the following organizations and companies: Japanese Society for Psoriasis Research, Amgen, Abbvie, Eisai, Taiho Yakuhin Kogyo, KyowaKirin, Maruho, and Sun Pharma.
Supporting Information
| Filename | Description |
|---|---|
| jde16737-sup-0001-Table S1.docxWord 2007 document , 12.1 KB |
Table S1. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Kubota K, Kamijima Y, Sato T, Ooba N, Koide D, Iizuka H, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015; 5:e006450.
- 2Kamiya K, Oiso N, Kawada A, Ohtsuki M. Epidemiological survey of the psoriasis patients in the Japanese Society for Psoriasis Research from 2013 to 2018. J Dermatol. 2021; 48: 864–75.
- 3Lin PT, Wang SH, Chi CC. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Sci Rep. 2018; 8: 16068.
- 4Tsuruta N, Narisawa Y, Imafuku S, Ito K, Yamaguchi K, Miyagi T, et al. Cross-sectional multicenter observational study of psoriatic arthritis in Japanese patients: relationship between skin and joint symptoms and results of treatment with tumor necrosis factor-alpha inhibitors. J Dermatol. 2019; 46: 193–8.
- 5Kaneko S, Tsuruta N, Yamaguchi K, Miyagi T, Takahashi K, Higashi Y, et al. Mycobacterium tuberculosis infection in psoriatic patients treated with biologics: real-world data from 18 Japanese facilities. J Dermatol. 2020; 47: 128–32.
- 6Bayaraa B, Imafuku S. Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University psoriasis registry. J Dermatol. 2019; 46: 389–98.
- 7Nestle FO, di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol. 2009; 9: 679–91.
- 8Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020; 323: 1945–60.
- 9Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012; 83: 1583–90.
- 10Rosmarin DM, Lebwohl M, Elewski BE, Gottlieb AB. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation consensus conference. J Am Acad Dermatol. 2010; 62: 838–53.
- 11Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol. 2007; 25: 535–46.
- 12Ogawa E, Okuyama R, Seki T, Kobayashi A, Oiso N, Muto M, et al. Epidemiological survey of patients with psoriasis in Matsumoto city, Nagano prefecture, Japan. J Dermatol. 2018; 45: 314–7.
- 13Burden AD, Warren RB, Kleyn CE, McElhone K, Smith CH, Reynolds NJ, et al. The British Association of Dermatologists' biologic interventions register (BADBIR): design, methodology and objectives. Br J Dermatol. 2012; 166: 545–54.
- 14Warren RB, Smith CH, Yiu ZZN, Ashcroft DM, Barker JNWN, Burden AD, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists biologic interventions register (BADBIR). J Invest Dermatol. 2015; 135: 2632–40.
- 15Menter A, Papp KA, Gooderham M, Pariser DM, Augustin M, Kerdel FA, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016; 30: 1148–58.
- 16Egeberg A, Ottosen MB, Gniadecki R, Broesby-Olsen S, Dam TN, Bryld LE, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018; 178: 509–19.
- 17Umezawa Y, Nobeyama Y, Hayashi M, Fukuchi O, Ito T, Saeki H, et al. Drug survival rates in patients with psoriasis after treatment with biologics. J Dermatol. 2013; 40: 1008–13.
- 18Kishimoto M, Komine M, Kamiya K, Sugai J, Mieno M, Ohtsuki M. Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan. J Dermatol. 2020; 47: 33–40.
- 19Ohata C, Ohyama B, Katayama E, Nakama T. Real-world efficacy and safety of interleukin-17 inhibitors for psoriasis: a single-center experience. J Dermatol. 2020; 47: 405–8.
- 20Kara Polat A, Oguz Topal I, Aslan Kayıran M, Koku Aksu AE, Aytekin S, Topaloglu Demir F, et al. Drug survival and safety profile of acitretin monotherapy in patients with psoriasis: a multicenter retrospective study. Dermatol Ther. 2021; 34:e14834.
- 21Puig L, Carrascosa JM, Daudén E, Sulleiro S, Guisado C. Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study. J Dermatolog Treat. 2020; 31: 344–51.
- 22Chularojanamontri L, Silpa-Archa N, Wongpraparut C, Limphoka P. Long-term safety and drug survival of acitretin in psoriasis: a retrospective observational study. Int J Dermatol. 2019; 58: 593–9.
- 23Kapniari E, Dalamaga M, Papadavid E. Comorbidities burden and previous exposure to biological agents may predict drug survival of apremilast for psoriasis in a real-world setting. Dermatol Ther. 2020; 33:e14168.
- 24Kishimoto M, Komine M, Kamiya K, Sugai J, Ohtsuki M. Drug survival of apremilast in a real-world setting. J Dermatol. 2019; 46: 615–7.
- 25Ohata C, Ohyama B, Kuwahara F, Katayama E, Nakama T. Real-world data on the efficacy and safety of apremilast in Japanese patients with plaque psoriasis. J Dermatolog Treat. 2019; 30: 383–6.
- 26Saruwatari H. Real-world experiences of apremilast in clinics for Japanese patients with psoriasis. J Dermatol. 2019; 46: 1166–9.
- 27Shalom G, Zisman D, Harman-Boehm I, Biterman H, Greenberg-Dotan S, Polishchuk I, et al. Factors associated with drug survival of methotrexate and acitretin in patients with psoriasis. Acta Derm Venereol. 2015; 95: 973–7.
- 28Ergun T, Seckin Gencosmanoglu D, Alpsoy E, Bulbul-Baskan E, Saricam MH, Salman A, et al. Efficacy, safety and drug survival of conventional agents in pediatric psoriasis: a multicenter, cohort study. J Dermatol. 2017; 44: 630–4.
- 29Lockshin B, Cronin A, Harrison RW, McLean RR, Anatale-Tardiff L, Burge R, et al. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: the Corrona psoriasis registry. Dermatol Ther. 2021; 34:e14808.
- 30Graier T, Salmhofer W, Jonak C, Weger W, Kölli C, Gruber B, et al. Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis. Br J Dermatol. 2021; 184: 1094–105.
- 31Sara A, Ignacio V, Fernández S, Martín JL, Charca L, Pino M, et al. Multicenter study of Secukinumab survival and safety in Spondyloarthritis and psoriatic arthritis: Secukinumab in Cantabria and ASTURias study. Front Med. 2021; 8:679009. https://doi.org/10.3389/fmed.2021
- 32Nawaf AM, Tarek N. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial. Expert Opin Biol Ther. 2014; 14: 749–56.
- 33Matthias A, Kristian R, Yamauchi P, Pinter A, Bagel J, Dahale S, et al. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. Br J Dermatol. 2022; 186: 942–54.
- 34Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists biologics and Immunomodulators register (BADBIR). Br J Dermatol. 2020; 183: 294–302.
- 35Alexander E, Nana AL, Lene D, Lørup EH, Nielsen ML, Nymand L, et al. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis – a nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum. 2022; 53:151979.
Citing Literature
